First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
Makoto Nishio(Japanese Foundation For Cancer Research), Hideaki Mizutani(Nippon Medical School), Kazuo Kasahara(Nippon Medical School), Toshihide Yokoyama(Kurashiki Central Hospital), Hidetoshi Hayashi(Kindai University), Ravi G. Gupta(Bristol-Myers Squibb (United States)), Katsuyuki Hotta(Okayama University Hospital), Isamu Okamoto(Kyushu University Hospital), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Satoshi Ikeda, Yuki Sato(Goethe University Frankfurt), Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Li Li(The University of Texas MD Anderson Cancer Center), Judith Bushong(Bristol-Myers Squibb (United States)), Hiroshi Tanaka(Tokyo Medical and Dental University), Tateaki Naito(Shizuoka Cancer Center)
Cited by 13
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k